In consideration, Aphria has agreed to pay a sales royalty of 5% Marijuana Stocks on any licensed CannaRoyalty products for a five-year term from date of first sale. Any such license would remain subject to the development of Canadian law to permit such uses of cannabis in Canada. “CannaRoyalty is a strategic and innovative company with an attractive suite of quality brands and products spanning the most important product categories for both the medical and recreational consumers,” said Vic Neufeld, CEO of Aphria. “We are pleased to be planning for the continued growth of our medical business and our entry into the recreational market with the strength of the CR Brands’ portfolio behind us.” Potential Canadian distribution of CR Brands’ products through Aphria is complemented by CannaRoyalty’s distribution channels in Puerto Rico and California. The Company’s Puerto Rico strategic partner, Natural Ventures PR, LLC has already both licensed and ordered products from CannaRoyalty. Moreover, in California, CannaRoyalty and River Wellness Inc. recently executed a binding term sheet that contemplates preferred distribution of the Company’s products, which includes a $15 million purchase commitment. CannaRoyalty will continue seeking additional distribution channels in other jurisdictions in North America and internationally. About CannaRoyalty CannaRoyalty is a fully integrated, active investor and operator in the legal cannabis sector. Our focus is to build and support a diversified portfolio of growth-ready assets in high-value segments of the cannabis sector, including research, consumer brands, devices and intellectual property. Our management team combines a hands-on understanding of the cannabis industry with seasoned financial know-how, assembling a platform of holdings via royalty agreements, equity interests, secured convertible debt and licensing agreements.